Pharma BD Deal Intelligence

Akcea Therapeutics, Inc. / Ionis Pharmaceuticals, Inc.

2018 · Licensing/Option · $1.7B · Complete

Ionis licensed worldwide rights to Akcea for inotersen (Tegsedi) and follow-on AKCEA-TTR-LRx in March 2018. Akcea paid $150M upfront in stock plus Ionis purchased $200M of Akcea common stock; total deal up to $1.7B including $1.3B in commercial milestones. Profit-sharing 60/40 in Ionis's favor for inotersen, transitioning to 50/50 after AKCEA-TTR-LRx launch.

Did it work? Outcome assessment

Assessment window: 5yr post-close.

Key facts

• Announced Mar 15, 2018
• Closed Apr 12, 2018
• Deal value $1.7B
• Deal type Licensing/Option
• Therapeutic area Hereditary transthyretin amyloidosis (hATTR)
• Indications Hereditary transthyretin amyloidosis (hATTR)
• Key assets Inotersen (Tegsedi) and AKCEA-TTR-LRx
• Mechanism Antisense oligonucleotide targeting transthyretin (TTR)

← Browse all deals  ·  How we score deals